Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads

a news article on how differences in the gut microbiome have been linked to an altered risk of developing low immune cell counts following treatment with Tecfidera.

He also reads a second article reporting that Tevogen Bio has announced plans to develop T-cell therapies that target the Epstein-Barr virus.

===================================

Are you interested in learning more about multiple sclerosis? If so, please visit:

https://multiplesclerosisnewstoday.com/

=====================================

To join in on conversations regarding multiple sclerosis, please visit:

https://multiplesclerosisnewstoday.com/forums/